Achondroplasia Treatment Market, by Treatment Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED: July 28, 2023

PAGES: 207 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The global achondroplasia treatment market is estimated to be valued at US$ 127.8 million in 2023 and is expected to exhibit a CAGR of 36.5% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 127.8 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	36.50%	2030 Value Projection:	US$ 1,126.0 Mn

Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.

Market Dynamics

Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.

Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.

Key features of the study:

This report provides an in-depth analysis of the global achondroplasia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Achondroplasia Treatment market based on the following parameters- Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.

Detailed Segmentation:

Global Achondroplasia Treatment Market, By Treatment Type:
- Vosoritide
- Human Growth Hormone
- Others
Global Achondroplasia Treatment Market, By Route of Administration:
- Oral
- Parenteral
Global Achondroplasia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Achondroplasia Treatment, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- BioMarin
- RIBOMIC
- Ascendis Pharma A/S
- BridgeBio Pharma, Inc.
- Pfizer Inc.
- PhaseBio Pharmaceuticals, Inc.
- SiSaf
- Novo Nordisk A/S
- F.Hoffmann-La Roche Ltd
- LG Chem
- Ferring B.V.
- JCR Pharmaceuticals Co., Ltd
- KVK TECH, INC.
- VIVUS LLC.
- ProLynx Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Ipsen Pharma
- Novartis AG
- Xiamen Amoytop Biotech Co., Ltd.

Product Code: CMI4161

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Achondroplasia Treatment Market, COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Achondroplasia Treatment Market, By Treatment Type, 2018 - 2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Vosoritide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Human Growth Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

6. Global Achondroplasia Treatment Market, By Route of Administration, 2018 - 2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Achondroplasia Treatment Market, By Distribution Channel, 2018 - 2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Achondroplasia Treatment Market, By Regions, 2018 - 2030 (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- BioMarin
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- RIBOMIC
- Ascendis Pharma A/S
- BridgeBio Pharma, Inc.
- Pfizer Inc.
- PhaseBio Pharmaceuticals, Inc.
- SiSaf
- Novo Nordisk A/S
- F.Hoffmann-La Roche Ltd
- LG Chem
- Ferring B.V.
- JCR Pharmaceuticals Co., Ltd
- KVK TECH, INC.
- VIVUS LLC.
- ProLynx Inc.
- Teva Pharmaceutical Industries Ltd.
- Ipsen Pharma
- Novartis AG
- Xiamen Amoytop Biotech Co., Ltd.